MDxHealth (NASDAQ: MDXH)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-26 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.050 | ||||||
REV | 6.106M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of MDxHealth (NASDAQ: MDXH) through any online brokerage.
Other companies in MDxHealth’s space includes: Fortress Biotech (NASDAQ:FBIO), Anixa Biosciences (NASDAQ:ANIX), Galectin Therapeutics (NASDAQ:GALT), OncoCyte (NASDAQ:OCX) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for MDxHealth (NASDAQ: MDXH) was reported by Oppenheimer on Monday, July 18, 2022. The analyst firm set a price target for 18.00 expecting MDXH to rise to within 12 months (a possible 120.32% upside). 4 analyst firms have reported ratings in the last year.
The stock price for MDxHealth (NASDAQ: MDXH) is $8.17 last updated Today at August 15, 2022, 2:35 PM UTC.
There are no upcoming dividends for MDxHealth.
MDxHealth’s Q2 earnings are confirmed for Friday, August 26, 2022.
There is no upcoming split for MDxHealth.
MDxHealth is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.